期刊文献+

利培酮片合用舒肝解郁胶囊对阴性症状为主精神分裂症患者认知功能的影响 被引量:8

The Effect of Risperidone Combined with Shuganjieyu Capsule on Cognitive Function of Schizophrenics with Negative Symptoms
原文传递
导出
摘要 目的比较单用利培酮片以及利培酮片合用舒肝解郁胶囊对阴性症状为主的精神分裂症患者认知及社会功能的影响及差异。方法采用阳性与阴性症状量表(PANSS)评定精神症状,威斯康星卡片分类测验(WCST)、连线测验(TMT)、大体功能评定量表(GAF)评定患者的认知及大体功能。结果入组8周合用组正确应答数、错误应答数、持续错误数、完成分类数、TMT-A及TMT-B完成时间、GAF分数(t=-3.117,2.851,2.870,-3.344,12.377,8.988,-18.308;P均<0.01),单用组TMT-A及TMT-B完成时间、GAF评分(t=8.930,7.170,-18.976;P均<0.001),与入组时比较差异有统计学意义;入组8周3组间正确应答数、错误应答数、持续错误数、完成分类数、TMT-A及TMT-B完成时间差异均有统计学意义(F=6.425,5.456,3.066,6.006,3.285,136.141,P均<0.05),合用组正确应答数、GAF分数高于单用组,持续错误数、TMT-B完成时间低于单用组,差异均有统计学意义(P<0.05)。结论利培酮片合用舒肝解郁胶囊对阴性症状为主的精神分裂症患者认知功能的改善优于单用利培酮片治疗。 Objective To compare the efficacy produced by risperidone alone and risperidone combined with shuganjieyu capsule on cognitive and social function of schizophrenics with negative symptoms. Methods Positive and Negative Syndrome Scale for schizophrenia was adopted to evaluate the efficacy of schizophrenics. Wisconsin Card Sorting Test, Trail Making Test, Global As- sessment Function were adopted to analyze the influence on cognitive and social function of schizophrenics after treatment. Results Patients in combination group at eight weekends had lower scores of number of error response,sustained error response,time of link,and higher scores of global assessment function and true response,accomplish classes than those at pre--treatment (t = 2. 851, 2. 870,12. 377,8. 988,-3. 117,-3. 344;P〈0.01). Patients in alone group at eight weekends had less time of link A and B,and higher scores of global assessment function than those at pre-treatment (t = 8. 930, 7. 170,-18. 976;P〈 0. 001). At the eighth week, patients in combination group had higher scores in number of error response, time of link than those in control group. Patients in alone group had higher scores in number of error response, sustained error response, time of link, and lower scores of true re- sponse,accomplish classes at the eighth week than those in control group (F= 6. 425,5. 456,3. 066,6. 006,3. 285,136. 141;P〈 0. 05). The number of true response,global assessment function at eight weekends in combination group were higher than those in alone group(P〈0. 05). The number of sustained error response ,time of link B at eight weekends in combination group were lower than those in alone group (P〈0. 05). Conclusion The efficacy on cognitive and social function of risperidone combined with shuganjieyu capsule is superior to risperidone alone in inproving cognitive function of schizophrenics with negative symptoms.
出处 《中国健康心理学杂志》 2013年第4期481-484,共4页 China Journal of Health Psychology
基金 河南省医学科技攻关计划(200803078)
关键词 精神分裂症 认知功能 舒肝解郁胶囊 抗抑郁剂 Schizophrenia Cognitive function Shuganjieyu capsule Antidepressant
  • 相关文献

参考文献14

  • 1Velligan D I, Bow- Thomas C C, Mahurin R K, et al. Do specific neurocognitive deficits predict specific domains of community func- tion in schizophrenia[J]? J Nerv Ment Dis, 2000,188 (8) : 518-524.
  • 2GaUetly C. Recent advances in treating cognitive impairment in schizophrenia[J]. Psychopharmacology, 2009,202(1-3) : 259-273.
  • 3Keefe R S, Bilder R M, Davis S M, et al. Neur.ocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial[J]. Arch Gen Psychiatry, 2007,64 (6) : 633-647.
  • 4Berk M,Gama C S,Sundram S,et al. Mirtazapine add--on therapy in the treatment of schizophrenia with atypical antipsychotics:A dou- ble -- blind, randomized, placebo- controlled clinical trial[J]. Hum Psychopharmacol, 2009,24 (3) : 233-238.
  • 5Massimo Biondi. Add--on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine [ J ]. Experimental and Clinical Psychopharmacology, 2007,15 ( 6 ) : 563-568.
  • 6Cho S J, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone:A randomized controlled trial[J]. Prog Neu- ropsychopharmacol Biol Psyehiatry, 2011,35 (1): 208- 211.
  • 7Iyo M,Shirayama Y,Watanabe H,et al. Fluvoxamine as a sigma--1 receptor agonist improved cognitive impairments in a patient with schizophrenia [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008,32(4) : 1072-1073.
  • 8Laakmann G, Jahn G, Schiile C. Hypericum perforatum extract in treatment of mild to moderate depression. Clinical and pharmacologi- cal aspects[J]. Nervenarzt,2002,73(7) :600-612.
  • 9Rhim Y T, Kim H,Yoon S J,et al. Effect of acanthopanax senticosus on 5--hydroxytryptamine synthesis and tryptophan hydroxylase ex- pression in the dorsal raphe of exercised rats[J]. J Ethnopharmacol, 2007,114(1) : 38-43.
  • 10Fujikawa T, Soya H, Hibasami H, et al. Effect of acanthopanax sen- ticosus harms on biogenie monoamine levels in the rat brain [J]. Phytother Res, 2002,16 (5): 474-478.

二级参考文献39

  • 1Schmidtke K, Schorb A, Winkelmann G. Cognitive frontal lobe dysfunction in obsessive-compulsive disorder. Biological Psychiatry, 1998, 43(9): 666-673
  • 2Mary S, Julie S. Executive function deficits associated with symptoms of schizotypy and obsessive-compulsive disorder. Psychiatry Research, 2002, 110:151-163
  • 3Goel V, Grafman J. Are the frontal lobes implicated in 'planning' functions? Interpreting data from the Tower of Hanoi. Neuropsychologia, 1995, 33(5): 623-642
  • 4Veale M, Sahakian J, Owen M. Specific cognitive deficits in tests sensitive to frontal lobe dysfunction in obsessive compulsive disorder. Psychol Med, 1996, 24: 1261-1269
  • 5Purcell, Rosemary, Maruff, Paul,et al.Cognitive deficits in obsessive compulsive disorder on tests of frontal striatal function. Biological Psychiatry, 1998, 43: 348-357
  • 6Flor-Henry P, John W. Cerebral Basis of Psychopathology. Boston, 1983
  • 7Berman I, Chang H, Klegon A. Is there a distinctive subtype of obsessive compulsive schizophrenia? Psychiatric Annals, 2000, 30: 649-652
  • 8Sobin C, Blundell L, Weiller F,et al.Evidence of schizotypy subtype in OCD. Journal of Psychiatric Research, 2000, 34: 15-24
  • 9Baxter J, Schwartz M. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive -compulsive disorder. Arch Gen Psychiatry, 1992, 49: 681-689
  • 10Scarone S, Colombo C, Livian S, et al. Increased right caudate nucleus size in obsessive-compulsive disorder (OCD) detection with magnetic resonance imaging. Psychiatry Research: Neuroimaging, 1992, 45: 115-121

共引文献20

同被引文献74

  • 1曲鸿儒.精神分裂症患者药物依从性影响因素的研究进展[J].医学信息(医学与计算机应用),2016,29(36):29-30. 被引量:2
  • 2范俭雄,耿德勤.精神病学[M].第2版.南京:东南大学出版社,2009:288.
  • 3Karadayi G, Emiroglu B, Ueok A. Relationship of symptomat-ie remission with quality of life and functionality in patients with schizophrenia. Comprehensive Psychialry, 2011,52(3): 701-707.
  • 4王来海,张瑞岭,张红星,等.帕利哌酮与利培酮治疗首发精神分裂症的临床疗效与安全性[J].中同医院用药评价与分析,2012,12(8):725-728.
  • 5Buckley PF,Miller BJ.Schizophrenia Research:A Progress Report[J].Psychiatr Clin North Am,2015 Sep,38(3):373-377.
  • 6Charzyńska K,Kucharska K,Mortimer A.Does employment promote the process of recovery from schizophrenia A review of the existing evidence[J].Int J Occup Med Environ Health,2015,28(3):407-418.
  • 7Klein C,Bespalov A.Development of novel therapy of schizophrenia in children and adolescents[J].Expert Opin Investig Drugs,2014,23(11):1531-1540.
  • 8刘芳,梁勋厂,罗浩,胡淑华,高珊荣,王增珍.离退休老年人抑郁症状的影响因素分析[J].中国社会医学杂志,2012,29(2):121-124. 被引量:7
  • 9钱建军,董莹盈,沈芳.利培酮对躯体化障碍的增效作用[J].中国药物与临床,2010,10(4):389-390. 被引量:17
  • 10韩自力,甘照宇,程敏锋,张明,钟智勇,吴小立,张晋碚.抗抑郁剂治疗过程中双相抑郁患者自杀意念、自杀未遂的风险因素分析[J].中华行为医学与脑科学杂志,2010,19(8):716-717. 被引量:6

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部